Preparation and application of recombinant human 2DK-Fc fusion protein
By designing the recombinant human 2DK-Fc fusion protein, fusing the IL-2 peptide and DK polypeptide with the IgG1-Fc fragment, the problems of poor permeability and insufficient stability of traditional anti-tumor drugs are solved, and high-efficiency targets for a variety of tumor cells are achieved Activation of killing and immunity has significantly improved the anti-tumor treatment effect.
Patent Information
- Application Number
- CN202010110890.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-02-24
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2040-02-24
AI Technical Summary
The existing anti-tumor drugs have poor permeability due to their large molecular size, which is prone to immunogenic reactions. In addition, the half-life of polypeptide drugs and poor stability in the body make it difficult to effectively target tumor cells.
A recombinant human 2DK-Fc fusion protein was designed, and the amino acid sequence of the IL-2 peptide and the DK polypeptide sequence were fused with the human IgG1-Fc fragment through genetic engineering technology. The protein A affinity chromatography method was used to purify the multi-dimensional method. Targeted therapy of tumor cells.
This fusion protein has specific high affinity, can recruit and activate NK cells, and has a killing effect on lung cancer, liver cancer, colorectal cancer, pancreatic cancer and breast cancer cells, extends the body's half-life, improves molecular utilization, enhances biological activity, and significantly improves the Anti-tumor immune effect.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The present invention relates to the field of genetic engineering, and specifically to a polypeptide-Fc fusion protein, a technology for constructing, expressing and purifying the fusion protein using genetic engineering principles, and an application of the fusion protein as a tumor therapeutic drug. Background Art
[0002] Cancer is a major disease that seriously threatens human life and social development. Antibody anti-tumor drugs are one of the fourth-generation tumor treatment methods after surgery, radiotherapy and chemotherapy, and are also the focus and main direction of innovative research and development.
[0003] Peptibody, or polypeptide-Fc fusion protein, is a highly potential alternative treatment for monoclonal antibodies. They are composed of the Fc segment of an antibody and a bioactive peptide grafted onto the Fc domain, that is, a new biotechnology product that can replace the function of an antibody by replacing the Fab segment of an antibody with a bioactive peptide. Of the same type of drugs, the only one currently on the market is AMG 531 (romiplostim) developed by Amgen, and there are currently no listed products in China. However, the research and development of this type of drug in the clinical trial stage is becoming more and more active, and there are currently 6 varieties, including AMG 386, AMG 819, AMG 706, Eptinezumab, Erenumab, and PINTA745. It can be seen that peptide body drugs are a research hotspot and frontier worldwide, and are about to usher in a period of rapid development.
[0004] Peptide drugs have revolutionized the design concept of traditional anti-tumor antibody drugs. They are fusions of the Fc domain specifically recognized by NK cells and tumor-targeting peptides. They overcome the shortcomings of traditional antibody drugs, such as poor permeability and easy immunogenicity due to their large molecules; at the same time, they also avoid the shortcomings of short half-life and poor in vivo stability of peptide drugs. They are a new type of biotechnology product with strong stability, long half-life in vivo, tumor targeting, and enhancement of NK inherent immune effects. They will gradually become the mainstream direction of global drug development in this century.
[0005] The present invention discloses a recombinant human 2DK-Fc fusion protein and a preparation method thereof. The fusion protein provided by the method can be used for treating tumors. Summary of the invention
[0006] The first object of the present invention is to provide a recombinant human 2DK-Fc fusion protein, wherein the amino terminus of the fusion protein is an amino acid sequence of an IL-2 peptide and two connected DK polypeptide sequences, the polypeptides are fused via a (GGG)3 connecting peptide, and the carboxyl terminus is a human IgG1-Fc fragment, the DK polypeptide repeat sequence and the Fc fragment are fused via a (GGG)3 connecting peptide, such as Figure 1Its amino acid sequence is shown in SEQ ID No.1.
[0007] The second object of the present invention is to provide a nucleic acid sequence encoding the above-mentioned recombinant human 2DK-Fc fusion protein, the gene sequence of which is shown in SEQ ID No.2.
[0008] The third object of the present invention is to provide a protein expression vector pCGS3-GS-2DK-Fc comprising the nucleic acid sequence shown in SEQ ID No.2, and its gene sequence is shown in SEQ ID No.3.
[0009] The fourth object of the present invention is to provide a method for producing the above-mentioned recombinant human 2DK-Fc fusion protein, which adopts the following technical scheme: inserting the nucleic acid sequence SEQ ID No. 2 into the animal cell expression vector pCGS3-CHOZN-GS by gene recombination technology, further introducing the nucleic acid sequence SEQ ID No. 2 into the mutant cell line CHOZN of the Chinese hamster cell CHO-K1 by electrotransfection, and then separating and purifying it; the nucleic acid sequence of the expression plasmid pCGS3-GS-2DK-Fc is shown in SEQID No. 3. Furthermore, the 2DK-Fc fusion protein is separated and purified by Protein A affinity chromatography.
[0010] The fifth object of the present invention is to provide the use of recombinant human 2DK-Fc fusion protein in tumor treatment. The fusion protein has high specific affinity with a variety of tumor cells and can recruit and activate NK cells. It is found that the fusion protein has a killing effect on lung cancer, liver cancer, colorectal cancer, pancreatic cancer and breast cancer cells, etc., and has great application value in the targeted treatment of the above tumors.
[0011] The sixth object of the present invention is to provide a structurally optimized derivative, which includes any structural optimization of the recombinant human 2DK-Fc fusion protein. The optimized derivative of the recombinant human 2DK-Fc fusion protein of the present invention is a product obtained by conventional modification of the amino acid side chain group or the amino or carboxyl end of the recombinant human 2DK-Fc fusion protein, or a product obtained by inserting or connecting a tag for protein detection or purification to the recombinant human 2DK-Fc fusion protein; preferably, the conventional modification is aminoation, amidation, hydroxylation, carboxylation, carbonylation, alkylation, acetylation, phosphorylation, sulfation, esterification, glycosylation, cyclization, biotinylation, fluorescent group modification, polyethylene glycol PEG modification or immobilization modification, etc.; preferably, the tag is His6, GST, EGFP, MBP, Nus, HA, FLAG, c-Myc or ProfinityeXact.
[0012] Therefore, in one aspect, the present invention provides a recombinant human 2DK-Fc fusion protein, characterized in that the recombinant human 2DK-Fc fusion protein is a fusion protein of a DK polypeptide repeat sequence and a human immunoglobulin IgG1-Fc fragment, wherein the DK polypeptide repeat sequence and the Fc fragment are fused via a linker; in one embodiment, the 2DK-Fc fusion protein comprises an amino acid sequence as shown in SEQID No.1.
[0013] In another aspect, the present invention provides a nucleic acid sequence encoding the recombinant human 2DK-Fc fusion protein, characterized in that the nucleic acid comprises the sequence shown in SEQ ID No.2.
[0014] In still another aspect, the present invention provides a vector, characterized in that it contains the nucleic acid sequence of the present invention.
[0015] In another aspect, the present invention provides a method for producing the human 2DK-Fc fusion protein of the present invention, characterized in that the sequence SEQ ID No. 2 is expressed in animal cells using the expression vector pCGS3-CHOZN-GS, and then the sequence is separated and purified by affinity chromatography; the sequence of the expression plasmid pCGS3-GS-2DK-Fc is shown in SEQ ID No. 3.
[0016] The present invention provides a composition comprising the recombinant human 2DK-Fc fusion protein of the present invention, the nucleic acid sequence encoding the recombinant human 2DK-Fc fusion protein of the present invention, the vector of the present invention and the method for producing the human 2DK-Fc fusion protein of the present invention.
[0017] The present invention provides use of the recombinant human 2DK-Fc fusion protein of the present invention in the treatment of lung cancer, liver cancer, colorectal cancer, pancreatic cancer and breast cancer.
[0018] The 2DK-Fc fusion protein described in the present invention is a highly potential alternative treatment form for monoclonal antibodies, and is a new drug that has both tumor targeting and immune enhancement effects. The recombinant human 2DK-Fc fusion protein carries out polypeptide modification by gene fusion, and fuses the tumor targeting peptide with the Fc segment. On the one hand, it specifically recognizes tumor cells through the tumor targeting peptide, and on the other hand, it achieves the core technical advantages of increasing stability, prolonging the half-life in the body, improving the utilization rate of molecules, and enhancing biological activity through the circulation pathway conducted by FcRn and increasing the molecular size. The product obtained by transformation has a significant enhancement effect on the body's NK cell-mediated anti-tumor immunity, and has a clear killing effect on lung cancer, liver cancer, colorectal cancer, pancreatic cancer and breast cancer cells in the presence of NK cells, and has a good application prospect in the future anti-tumor drug market. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The above is only an overview of the technical solution of the present invention. In order to more clearly understand the technical means of the present invention, the present invention is further described in detail below in conjunction with specific implementation methods.
[0020] Figure 1 This is a schematic diagram of the peptide structure design
[0021] Figure 2 This is a diagram of the structure of the recombinant plasmid for expressing 2DK-Fc fusion protein.
[0022] Figure 3 This is the result of gel electrophoresis of nucleic acid of the recombinant plasmid expressing 2DK-Fc fusion protein.
[0023] Figure 4 This is the SDS electrophoresis detection result of 2DK-Fc fusion protein.
[0024] Figure 5 This is the result of liquid-mass sequencing of 2DK-Fc fusion protein.
[0025] Figure 6 These are the confocal detection results of the targeted binding of 2DK-Fc fusion protein to various tumor cell lines.
[0026] Figure 7 These are the results of cytotoxicity experiments on the killing effect of 2DK-Fc fusion protein on various tumor cell lines. DETAILED DESCRIPTION
[0027] The preferred embodiments of the present invention are described below in conjunction with the accompanying drawings. It should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0028] The present invention mainly uses genetic engineering technology to construct a eukaryotic expression vector pCGS3-GS-2DK-Fc of a fusion protein, introduces the expression vector into a mutant cell line CHOZN of a Chinese hamster cell CHO-K1 by electroporation transfection, expresses and purifies a 2DK polypeptide repeat sequence and a human immunoglobulin IgG1-Fc fragment fusion protein 2DK-Fc, and further detects the therapeutic effect of 2DK-Fc on a variety of tumors. The amino acid sequence of the 2DK-Fc fusion protein is shown in SEQ ID No. 1. The coding sequence of the human immunoglobulin IgG1-Fc fragment is shown in SEQ ID No. 4. The connecting peptide (GGG) 3 connecting peptide sequence is shown in SEQ ID No. 5.
[0029] Example 1: Preparation of 2DK-Fc fusion protein
[0030] The preparation process of 2DK-Fc fusion protein mainly includes gene cloning, vector construction, cell transfection, fusion protein expression and purification.
[0031] 1.1 Gene cloning
[0032] The vector plasmid pFUSE-IgG1-Fc-2DK (SEQ ID No. 6) of 2DK-Fc fusion protein was constructed by genetic engineering technology, as shown in the attached Figure 2 Next, the vector plasmid of pFUSE-IgG1-Fc-2DK was synthesized at a gene synthesis professional company (Shanghai Sangon Biotechnology Co., Ltd.).
[0033] 1.2 Construction of fusion protein expression plasmid pCGS3-GS-2DK-Fc
[0034] 1.2.1 Obtaining the target gene fragment of the fusion protein
[0035] The target fragment of 2DK-Fc fusion protein was amplified by PCR technology using primers with restriction endonuclease Hind III and Xhol sequences.
[0036] The PCR system was (100 μl system): 25 μl of 5× buffer, 2.5 μl of 10 mM dNTP, 1 μl of each forward and reverse primer, 2 μl of template, 1.5 μl of Phusion High-Fidelity DNA Ploymerase, and 92 μl of ddH2O.
[0037] The PCR conditions were as follows: pre-denaturation at 98°C for 30 s, denaturation at 98°C for 10 s, annealing at 60°C for 15 s, extension at 72°C for 40 s, further extension at 72°C for 5 min, and storage at 4°C.
[0038] The PCR product was added to 10X loading buffer and then subjected to agarose gel electrophoresis to recover the target fragment. The recovered target fragment was purified using the QIAquick PCR purification kit (QIAGEN). The concentration of the purified DNA fragment was determined using an ultraviolet spectrophotometer.
[0039] 1.2.2 Obtaining enzyme-digested fragments
[0040] The synthetic 2DK-Fc fusion protein gene coding fragment and the expression vector pCGS3-CHOZN-GS were double-digested with restriction endonucleases Hind III and Xhol, respectively. The enzyme digestion system (50 μl) was as follows: 1 μg of the amplified 2DK-Fc fragment and pCGS3-CHOZN-GS vector were added to two PCR tubes, and Hind III 1 μl, Xhol 1 μl, 10× buffer 5 μl and ddH2O 42 μl were added, respectively.
[0041] Digest at 37℃ for 10-40min, and add 10μl 6×Gel loading to terminate the reaction. Add 10X loading buffer to the digested product and perform agarose gel electrophoresis to recover the large fragments. Use QIAquick PCR purification kit (QIAGEN) to purify the recovered large fragments. Use UV spectrophotometer to measure the concentration of purified double-stranded DNA fragments.
[0042] 1.2.3 Ligation reaction
[0043] The digested fragments obtained above were ligated with T4 DNA ligase. The ligation system (10 μl) was as follows: 1 μl 10X T4 DNA ligase buffer, 4 μl synthetic 2DK-Fc double digested fragment, 3.5 μl pCGS3-CHO ZN-GS double digested vector fragment, 1.5 μl T4 DNA ligase. The reaction was carried out at 16°C overnight.
[0044] 1.3 Transformation of competent bacteria
[0045] Take out 50μl competent cells from the -80℃ refrigerator and thaw on ice. Take 2μl of the ligation product prepared by the above ligation reaction and add it to the competent cells. After gently mixing, add the bacterial solution to a 2mm electroporation cuvette for electroporation. After electroporation, aspirate the bacterial solution and add it to 1ml LB medium. After mixing, shake and culture at 37℃, 250rpm for 1h. After 1h, take 300μl of the bacterial solution and apply it to the LB plate containing Amp. Incubate it upside down at 37℃ for 16h.
[0046] Pick the positive clones and culture them in LB medium containing Amp for 16 hours for amplification. Add 80% glycerol to a part of the bacterial solution and freeze it in a -20℃ refrigerator, and send the other part of the bacterial solution directly to the detection sequence. The sequencing primer sequences are as follows: upstream sequencing primer: CGTAAGCTTATGTACAGGATGCAACTCCTGT CTTGC (SEQ ID No.7); downstream sequencing primer: TGCTCGAGTCATTTACCCGGAGA CAGG (SEQ ID No.8). The clone bacteria with correct sequencing are marked as pCGS3-GS-2DK-Fc, and conventional shaking amplification is performed. The plasmid is extracted with a high-purity plasmid mini-extraction kit (QIAGEN), and the concentration is determined by a UV spectrophotometer. The extracted plasmid is added to 10X loading buffer and mixed, and then subjected to agarose gel electrophoresis. The results are shown in the attached figure. Figure 3 .
[0047] 1.4 Construction of Stable-Pool
[0048] Resuscitate CHOZN cells to shake flasks, culture with 30 ml CD Fusion + 6 mM glutamine medium, and subculture for no less than 3 times. Keep the cells in the doubling phase with a survival rate of more than 95%.
[0049] Take 50 μg of the constructed pCGS3-GS-2DK-Fc plasmid and mix it with about 10 7 Mix 10 cells in 0.5 ml opti-MEM medium, take 400 μl of the cell mixture and add it to a 0.4 mm electroporation cuvette, transfer the plasmid into CHOZN cells by electroporation, and then add the cells to a T25 culture flask for culture. When the viability recovers to more than 90% and the doubling time recovers to 18h to 24h, freeze 1x10 7 The cells were labeled as 2DK-Fc SP (stable cell bank).
[0050] 1.5 Protein expression
[0051] Take 2DK-Fc SP and revive it in a 37°C water bath, add it to 30 ml CD Fusion culture medium, culture it, subculture it until the cell viability rises to more than 90%, expand it to 250 ml shake flask, and gradually expand it to 1000 ml shake flask. When the viability drops below 70%, terminate the culture and take the supernatant by centrifugation.
[0052] 1.6 2DK-Fc protein purification
[0053] Prepare purification buffer: balancing solution 20mM Tris-HCl, 50mM NaCl (pH7.0±0.1), eluting solution 0.1M Glycine-HCl, 50mM NaCl (pH3.5±0.1), pH adjuster 1M Tris (pH8.5), column cleaning solution 0.1M H3PO4 and pipeline cleaning solution 0.1M NaOH / 0.3M NaOH.
[0054] Connect the Protein A chromatography column to the AKTA Purifier Chromatography System (GE Healthcare Life Science). Equilibrate the chromatography column with the equilibrium solution at a flow rate of 2-10 ml / min. Load the culture supernatant after ultrafiltration and concentration at a flow rate of 2-5 ml / min. After loading, the equilibrium solution re-equilibrates the chromatography column at a flow rate of 2-10 ml / min. After equilibrium, elute with the eluent at a flow rate of 2-10 ml / min. Collect the elution peak and adjust the pH to 7.0 ± 0.1 with a pH adjuster. Determine the protein concentration using a UV spectrophotometer. Store in a -20°C refrigerator.
[0055] 1.7 Protein desalting and purification
[0056] Connect the desalting column to the AKTA Purifier Chromatography System (GE Healthcare Life Science). Balance the column with purified water, and load the protein after filtering through the filter membrane at a flow rate of 2-5 ml / min. After loading, elute with purified water at a flow rate of 2-10 ml / min. Collect the elution peak and adjust the pH to 7.0±0.1 with a pH adjuster. Determine the protein concentration using a UV spectrophotometer. Store in a refrigerator at -20°C. Detect the purified fusion protein by SDS-PAGE gel electrophoresis. The results are shown in the attached figure. Figure 4 At the same time, the purified fusion protein was sent for sequencing, and the sequencing results were compared with the original sequence. The results are shown in the attached Figure 5 .
[0057] Example 2: Targeted killing effect of 2DK-Fc fusion protein on various tumor cell lines
[0058] 2.1 Confocal detection of the targeting binding effect of 2DK-Fc fusion protein on various tumor cell lines
[0059] (1) Cell plating: human normal intestinal epithelial cells HIEC, normal lung epithelial cells HBE, human embryonic pancreatic tissue-derived cells CCC-HPE, normal liver epithelial cells HL-7702 and normal breast epithelial cells MCF-10A, as well as human colon cancer cells HCT116, human lung cancer cells A549, human pancreatic cancer cells PANC-1, human liver cancer cells Bel-7402 and human breast cancer cells MDA-MB-231 were plated in six-well plates for use;
[0060] (2) Fixation: Fix with 4% paraformaldehyde for 15 min;
[0061] (3) Blocking: discard 4% paraformaldehyde, wash twice with PBS, and block with 3% BSA / PBS at 37°C for 30 min;
[0062] (4) 2DK-Fc fusion protein incubation: After wiping the blocking solution, add 2DK-Fc fusion protein and incubate at 37°C for 1 h;
[0063] (5) Primary antibody incubation: After washing with PBS three times, add anti-Fc antibody and incubate at 37°C for 1 h;
[0064] (6) Fluorescent secondary antibody incubation: After washing with PBS three times, add FITC-labeled fluorescent secondary antibody and incubate at 37°C for 30 min;
[0065] (5) DAPI staining: wash three times with PBS, add 100 μl of DAPI, incubate at room temperature for 15 min;
[0066] (6) Sealing: After washing three times with PBS, seal the slides with anti-fade mounting medium.
[0067] (7) Experimental results: 2DK-Fc fusion protein has strong binding ability with human colon cancer cells HCT116, human lung cancer cells A549, human pancreatic cancer cells PANC-1, human liver cancer cells Bel-7402 and human breast cancer cells MDA-MB-231, but almost no binding with human normal intestinal epithelial cells HIEC, normal lung epithelial cells HBE, human embryonic pancreatic tissue-derived cells CCC-HPE, normal liver epithelial cells HL-7702 and normal breast epithelial cells MCF-10A. The results are shown in the attached figure. Figure 6 .
[0068] 2.2 Cytotoxicity assay to detect the killing effect of 2DK-Fc fusion protein on various tumor cell lines
[0069] (1) Cell plating: Tumor target cells and effector cells were incubated with recombinant proteins in a 96-well plate according to the ratio, and two effector-target ratios of 2:1 and 20:1 were selected. The plating groups are as follows:
[0070] ① Target cell group;
[0071] ②Effector cell group;
[0072] ③Blank group: target cells + effector cells;
[0073] ④Fc protein group: target cells + effector cells + Fc protein;
[0074] ⑤2DK-Fc recombinant protein group: target cells + effector cells + 2DK-Fc recombinant protein;
[0075] ⑥Positive group: only add target cells;
[0076] ⑦ Background group: only culture medium was added.
[0077] After plating according to the groups and different effector-target ratios, 3 replicate wells were prepared for each group, and the 96-well plates were placed in an incubator at 37°C and 5% CO2 for culture.
[0078] (2) After 5 hours of incubation, add 20 μl of LDH release reagent to each well of the positive group and return to the incubator for another 1 hour. After 6 hours, remove the 96-well plate and centrifuge at 400 g for 5 minutes. Take 120 μl of supernatant from each well and place it in a new 96-well plate. Add 60 μl of detection solution to each well. After mixing, incubate at 37°C, 200 r in a shaker in the dark for 30 minutes. Measure the absorbance at 490 nm, and use 600 nm or greater as the reference wavelength.
[0079] (3) Calculate the killing rate of effector cells against target cells according to the formula:
[0080] Kill rate (%) = (③ or ④ or ⑤ - ① - ② + ⑦) ÷ (⑥ - ①) × 100%
[0081] (4) Experimental results: The killing rate of 2DK-Fc fusion protein on normal epithelial cells of the above five tissues was not statistically significant compared with the untreated group (p>0.05), indicating that 2DK-Fc fusion protein had no killing effect on normal epithelial cells; while the killing rate on five tumor cells, including human colon cancer cell HCT116, human lung cancer cell A549, human breast cancer cell MDA-MB-231, human pancreatic cancer cell PANC-1 and human liver cancer cell Bel-7402, was statistically significant (p<0.05), indicating that 2DK-Fc fusion protein had a significant killing effect on tumor cells. The results are shown in the attached figure. Figure 7 . Sequence Listing <110> Shenyang Medical Life Science Co., Ltd. <120> Preparation and application of recombinant human 2DK-Fc fusion protein <160> 6 <170> SIPOSequenceListing 1.0 <210> 1 <211> 279 <212> PRT <213> Artificial sequence <400> 1 Met Tyr Arg Met Gln Leu Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu 1 5 10 15 Val Thr Asn Ser Asp Tyr His Asp Pro Ser Leu Pro Thr Leu Arg Lys 20 25 30 Gly Gly Gly Asp Tyr His Asp Pro Ser Leu Pro Thr Leu Arg Lys Gly 35 40 45 Gly Gly Arg Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro 50 55 60 Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 65 70 75 80 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 85 90 95 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 100 105 110 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 115 120 125 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 130 135 140 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 145 150 155 160 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 165 170 175 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys 180 185 190 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 195 200 205 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 210 215 220 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 225 230 235 240 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 245 250 255 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 260 265 270 Leu Ser Leu Ser Pro Gly Lys 275 <210> 2 <211> 840 <212> DNA <213> Artificial sequence <400> 2 atgtacagga tgcaactcct gtcttgcatt gcactaagtc ttgcacttgt cacgaattcg 60 gactaccacg atccaagcct gcccaccctg agaaagggcg gcggagacta ccacgatcct 120 tctctgccta cactgagaaa aggaggaggc agatctgaca aaactcacac atgcccaccg 180 tgcccagcac ctgaactcct ggggggaccg tcagtcttcc tcttcccccc aaaacccaag 240 gacaccctca tgatctcccg gacccctgag gtcacatgcg tggtggtgga cgtgagccac 300 gaagaccctg aggtcaagtt caactggtac gtggacggcg tggaggtgca taatgccaag 360 acaaagccgc gggaggagca gtacaacagc acgtaccgtg tggtcagcgt cctcaccgtc 420 ctgcaccagg actggctgaa tggcaggag tacaagtgca aggtctccaa caagccctc 480 ccagccccca tcgagaaaac catctccaaa gccaaagggc agccccgaga accacaggtg 540 tacaccctgc cccatcccg ggaggagatg accagaacc aggtcagcct gacctgcctg 600 gtcaaggct tctatcccag cgacatcgcc gtggagtggg agagcaatgg gcagccggag 660 aacaactaca agaccacgcc tcccgctg gactccgacg gctccttct cctctacagc 720 aagctcaccg tggacagag caggtggcag cagggaacg tcttcatg ctccgtgatg 780 cacgaggctc tgcacaacca ctacacgcag agagcctct ccctgtctcc gggtaaatga 840 <210> 3 <211> 10387 <212> DNA <213> Artificial sequence <400> 3 tcgacctcgg gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca 60 caaaaatcga cgctcaagtc agaggtggcg aaacccgaca ggacttaa gataccaggc 120 gtttccccct ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata 180 cctgtccgcc tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta 240 tctcagttcg gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca 300 gcccgaccgc tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga 360 cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg 420 tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg 480 tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg 540 caaacaaacc accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag 600 aaaaaaagga tctcaagaag atcctttgat ctttctctacg gggtctgacg ctcagtggaa 660 cgaaaactca cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat 720 ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc 780 tgacagttac caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc 840 atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc 900 tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc 960 aaaaccag ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgccctc 1020 catccagtct atttattgtt gccgggaagc tagtagt agttcgccag ttaatagtttt 1080 gcgcaacgtt gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt ttggtatggc 1140 ttcattcagc tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa 1200 aaagcggtt agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt 1260 atcactcatg gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg 1320 cttttctgtg actggtgagt actcaaccaa gtcattctga gatagtgta tgcggcgacc 1380 gagttgctct tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa 1440 agtgctcatc attggaaac gttcttcggg gcgaaactc tcaggatct taccgctgtt 1500 gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt 1560 caccagcgtt tctgggtgag aaaaacagg aaggcaaat gccgcaaaa agggaatag 1620 ggcgacacgg aaatgttgaa tactcatact cttcctttt caatattat gaagcattta 1680 tcagggttat tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaaaat 1740 aggggttccg cgcacatttc cccgaaaagt gccacctgac gtctaagaaa ccattattat 1800 catgacatta acctataaaa ataggcgtat cacgaggccc tgatggctct ttgcggcacc 1860 catcgttcgt aatgttccgt ggcaccgagg acaaccctca agaaaaatg taatcacact 1920 ggctcacctt cgggtgggcc tttctgcgtt tatagaga cactttatgt ttaagaaggt 1980 tggtaaattc cttgcggctt tggcagccaa gctagatccg gctgtggaat gtgtgtcagt 2040 tagggtgtgg aaagtcccca ggctccccag caggcagaag tatgcaaagc atgcatctca 2100 attagtcagc aaccaggtgt ggaaagtccc caggctcccc agcaggcaga agtatgcaaa 2160 gcatgcatct caattagtca gcaaccatag tcccgcccct aactccgcccc atcccgcccc 2220 taactccgcc cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg 2280 cagaggccga ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg 2340 gaggcctagg cttttgcaaa aagctagctt ggggccaccg ctcagagcac cttccaccat 2400 ggccacctca gcaagttccc acttgaacaa aaacatcaag caaatgtact tgtgcctgcc 2460 ccagggtgag aaagtccaag ccatgtatat ctgggttgat ggtactggag aaggactgcg 2520 ctgcaaaacc cgcaccctgg actgtgagcc caagtgtgta gaagagttac ctgagtggaa 2580 ttttgatggc tctagtacct ttcagtctga gggctccaac agtgacatgt atctcagccc 2640 tgttgccatg tttcgggacc ccttccgcag agatcccaac aagctggtgt tctgtgaagt 2700 tttcaagtac aaccggaagc ctgcagagac caatttaagg cactcgtgta aacggataat 2760 ggacatggtg agcaaccagc acccctggtt tggaatggaa caggagtata ctctgatggg 2820 aacagatggg cacccttttg gttggccttc caatggcttt cctgggcccc aaggtccgta 2880 ttactgtggt gtgggcgcag acaaagccta tggcagggat atcgtggagg ctcactaccg 2940 cgcctgcttg tatgctgggg tcaagattac aggaacaaat gctgaggtca tgcctgccca 3000 gtgggagttc caaataggac cctgtgaagg aatccgcatg ggagatcatc tctgggtggc 3060 ccgtttcatc ttgcatcgag tatgtgaaga ctttggggta atagcaacct ttgaccccaa gcccattcct gggaactgga atggtgcagg ctgccatacc aactttagca ccaaggccat 3180. gcgggaggag aatggtctga agcacatcga ggaggccatc gagaactaa gcaagcggca ccggtaccac attcgagcct acgatcccaa ggggggcctg gacaatgccc gtcgtctgac 3300 3360. tgggttccac gaaacgtcca acatcaacga cttttctgct ggtgtcgcca atcgcagtgc cagcatccgc attccccgga ctgtcggcca ggagaagaaa ggttactttg aagaccgccg cccctctgcc aattgtgacc cctttgcagt gacagaagcc atcgtccgca catgccttct caatgagact ggcgacgagc ccttccaata caaaactaa ttagactttg agtgatcttg agcctttcct agttcatccc accccgcccc aggagatct ttgtgaagga accttacttc 3600 tgtggtgtga cataattgga caaactacct acagagattt aaagctctaa ggtaaatata aaatttttaa gtgtataatg tgttaaacta ctgattctaa ttgtttgtgt attttagatt ccaacctatg gaactgatga atgggagcag tggtggaatg cctttaatga ggaaaacctg ttttgctcag aagaaatgcc atctagtgat gatgaggcta ctgctgactc tcaacattct 3840 actcctccaa aaaagaagag aaaggtagaa gaccccaagg actttccttc agaattgcta 3900 agttttttga gtcatgctgt gtttagtaat agaactcttg cttgctttgc tatttacacc 3960 acaaaggaaa aagctgcact gctatacaag aaaattatgg aaaaatattc tgtaaccttt 4020 ataagtaggc ataacagtta taatcataac atactgtttt ttcttactcc acacaggcat 4080 agagtgtctg ctattaataa ctatgctcaa aaattgtgta cctttagctt tttaatttgt 4140 aaaggggtta ataaggaata tttgatgtat agtgccttga ctagagatca taatcagcca 4200 taccacattt gtagaggttt tacttgcttt aaaaaacctc ccacacctcc ccctgaacct 4260 gaaacataaa atgaatgcaa ttgttgttgt taacttgttt attgcagctt ataatggtta 4320 caaataaagc aatagcatca caaatttcac aaataaagca tttttttcac tgcattctag 4380 ttgtggtttg tccaaactca tcaatgtatc ttatcatgtc tggatctagc ttcgtgtcaa 4440 ggacggtgac tgcagtgaat aataaaatgt gtgtttgtcc gaaatacgcg ttttgagatt 4500 tctgtcgccg actaaattca tgtcgcgcga tagtggtgtt tatcgccgat agagatggcg 4560 atattggaaa aatcgatatt tgaaaatatg gcatattgaa aatgtcgccg atgtgagttt 4620 ctgtgtaact gatatcgcca tttttccaaa agtgattttt gggcatacgc gatatctggc 4680 gatagcgctt atacgttta cgggggatgg cgatagacga ctttggtgac ttgggcgatt 4740 ctgtgtgtcg caaatatcgc agttcgata taggtgacag acgatatgag gctatatcgc 4800 cgatagaggc gacatcaagc tggcacatgg ccaatgcata tcgatctata cattgaatca 4860 atattggcca ttagccatat tattcattgg ttatatagca taaatcaata ttggctattg 4920 gccattgcat acgttgtatc catatcataa tatgtacatt tatattggct catgtccaac 4980 attaccgcca tgttgacatt gattattgac tagttattaa tagtaatcaa ttacggggtc 5040 attagttcat agcccatata tggagttccg cgttacataa cttacggtaa atggcccgcc 5100 tggctgaccg cccaacgacc cccgcccatt gacgtcaata atgacgtatg ttcccatagt 5160 aacgccaata gggactttcc attgacgtca atgggtggag tatttacggt aaactgccca 5220 cttggcagta catcaagtgt atdatagcc aagtacgccc cctattgacg tcaatgacgg 5280 taaatggccc gcctggcatt atgcccagta catgacctta tgggactttc ctacttggca 5340 gtacatctac gtattagtca tcgctattac catggtgatg cggttttggc agtacatcaa 5400 tgggcgtgga tagcggtttg actcacgggg atttccaagt ctccacccca ttgacgtcaa 5460 tgggagtttg ttttggcacc aaaatcaacg ggactttcca aaatgtcgta acaactccgc 5520 cccattgacg caaatgggcg gtaggcgtgt acggtgggag gtctatataa gcagagctcg 5580 tttagtgaac cgtcagatcg cctggagacg ccatccacgc tgttttgacc tccatagaag 5640 acaccgggac cgatccagcc tccgcggccg ggaacggtgc attggaacgc ggattccccg 5700 tgccaagagt gacgtaagta ccgcctatag agtctatagg cccaccccct tggcttctta 5760 tgcatgctat actgtttttg gcttggggtc tatacacccc cgcttcctca tgttataggt 5820 gatggtatag cttagcctat aggtgtgggt tattgaccat tattgaccac tcccctattg 5880 gtgacgatac tttccattac taatccataa catggctctt tgccacaact ctctttattg 5940 gctatatgcc aatacactgt ccttcagaga ctgacacgga ctctgtattt ttacaggatg 6000 gggtctcatt tattattac aaattcacat atacaacacc accgtcccca gtgcccgcag 6060 ttttattaa acataacgtg ggatctccac gcgaatctcg ggtacgtgtt ccggacatgg 6120 gctcttctcc ggtagcggcg gagcttctac atccgagccc tgctcccatg cctccagcga 6180 ctcatggtcg ctcggcagct cttgctcct aacagtggag gccagactta ggcacagcac 6240 gatgcccacc accaccagtg tgccgcacaa ggccgtggcg gtagggtatg tgtctgaaaa 6300 tgagctcggg gagcgggctt gcaccgctga cgcatttgga agacttaagg cagcggcaga 6360 agaagatgca ggcagctgag ttgttgtgtt ctgataagag tcagaggtaa ctcccgttgc 6420 ggtgctgtta acggtggagg gcagtgtagt ctgagcagta ctcgttgctg ccgcgcgc 6480 caccagacat atagctgac agactaacag actgttcctt tccatgggtc ttttctgcag 6540 tcaccgtcct tgacacgaag cttatgtaca ggatgcaact cctgtcttgc attgcactaa 6600 gtcttgcact tgtcacgaat tcggactacc acgatccaag cctgcccacc ctgagaaagg 6660 gcggcggaga ctaccacgat ccttctctgc ctacactgag aaaaggagga ggcagatctg 6720 acaaaactca cacatgccca ccgtgcccag cacctgaact cctgggggga ccgtcagtct 6780 tcctcttccc cccaaaaccc aaggacaccc tcatgatctc ccggacccct gaggtcacat 6840 gcgtggtggt ggacgtgagc cacgaagacc ctgaggtcaa gttcaactgg tacgtggacg 6900 gcgtggaggt gcataatgcc aagacaaagc cgcgggagga gcagtacaac agcacgtacc 6960 gtgtggtcag cgtcctcacc gtcctgcacc aggactggct gaatggcaag gagtacaagt 7020 gcaaggtctc caacaaagcc ctcccagccc ccatcgagaa aaccatctcc aaagccaaag 7080 ggcagccccg agaaccacag gtgtacaccc tgcccccatc ccgggaggag atgaccaaga 7140 accaggtcag cctgacctgc ctggtcaaag gcttctatcc cagcgacatc gccgtggagt 7200 gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg ctggactccg 7260 acggctcctt cttcctctac agcaagctca ccgtggacaa gagcaggtgg cagcagggga 7320 acgtcttctc atgctccgtg atgcacgagg ctctgcacaa ccactacacg cagaagagcc 7380 tctccctgtc tccgggtaaa tgactcgagt acgatagccg gctaatcagc cataccacat 7440 ttgtagaggt tttacttgct ttaaaaaacc tcccacacct ccccctgaac ctgaaacata 7500 aaatgaatgc aattgttgtt gttaacttgt ttattgcagc ttataatggt tacaaataaa 7560 gcaatagcat cacaaatttc acaaataaag catttttttc actgcattct agttgtggtt 7620 tgtccaaact catcaatgta tcttatcatg tctggaattc ggacggtgac tgcagtgaat 7680 aataaaatgt gtgtttgtcc gaaatacgcg ttttgagatt tctgtcgccg actaaattca 7740 tgtcgcgcga tagtggtgtt tatcgccgat agagatggcg atattggaaa aatcgatatt 7800 tgaaaatatg gcatattgaa aatgtcgccg atgtgagttt ctgtgtaact gatatcgcca 7860 tttttccaaa agtgattttt gggcatacgc gatatctggc gatagcgctt atatcgttta 7920 cgggggatgg cgatagacga ctttggtgac ttgggcgatt ctgtgtgtcg caaatatcgc 7980 agtttcgata taggtgacag acgatatgag gctatatcgc cgatagaggc gacatcaagc 8040 tggcacatgg ccaatgcata tcgatctata cattgaatca atattggcca ttagccatat 8100 tattcattgg ttatatagca taaatcaata ttggctattg gccattgcat acgttgtatc 8160 catatcataa tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt 8220 gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata 8280 tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc 8340 cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc 8400 attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt 8460 atcatatgcc aagtacgcccc cctattgacg tcaatgacgg taaatggccc gcctggcatt 8520 atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca 8580 tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg 8640 actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc 8700 aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg 8760 gtaggcgtgt acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg 8820 cctggagacg ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc 8880 tccgcggccg ggaacggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta 8940 ccgcctatag agtctatagg cccaccccct tggcttctta tgcatgctat actgtttttg 9000 gcttggggtc tatacacccc cgcttcctca tgttataggt gatggtatag cttagcctat 9060 aggtgtgggt tattgaccat tattgaccac tcccctattg gtgacgatac tttccattac 9120 taatccataa catggctctt tgccacaact ctctttattg gctatatgcc aatacactgt 9180 ccttcagaga ctgacacgga ctctgtattt ttacaggatg gggtctcatt tattatttac 9240 aaattcacat atacaacacc accgtcccca gtgcccgcag tttttattaa acataacgtg 9300 ggatctccac gcgaatctcg ggtacgtgtt ccggacatgg gctcttctcc ggtagcggcg 9360 gagcttctac atccgagccc tgctcccatg cctccagcga ctcatggtcg ctcggcagct 9420 ccttgctcct aacagtggag gccagactta ggcacagcac gatgcccacc accaccagtg 9480 tgccgcacaa ggccgtggcg gtagggtatg tgtctgaaaa tgagctcggg gagcgggctt 9540 gcaccgctga cgcatttgga agacttaagg cagcggcaga agaagatgca ggcagctgag 9600 ttgttgtgtt ctgataagag tcagaggtaa ctcccgttgc ggtgctgtta acggtggagg 9660 gcagtgtagt ctgagcagta ctcgttgctg ccgcgcgcgc caccagacat atagctgac 9720 agactaacag actgttcctt tccatgggtc ttttctgcag tcaccgtcct tgacacgaag 9780 ttcgaatcag gataagggcg aattccgacg taggcctatt cgaagtctac ttaattaagg 9840 gggaggctaa ctgaaacacg gaaggagaca ataccggaag gaacccgcgc tatgacggca 9900 ataaaaagac agaataaaac gcacgggtgt tgggtcgttt gttcataaac gcggggttcg 9960 gtcccagggc tggcactctg tcgatacccc accgagaccc cattggggcc atacgcccg 10020 cgtttcttcc ttttccccac cccacccccc aagttcgggt gaaggcccag ggctcgcagc 10080 caacgtcggg gcggcaggcc ctgccatagc ggatcctcta cgccggacgc atcgtggccg 10140 gcatcaccgg cgccacaggt gcggttgctg gcgcctatat cgccgacatc accgatgggg 10200 aagatcgggc tcgccacttc gggctcatga gcgcttgttt cggcgtgggt atggtggcag 10260 gccccgtggc cggggactg ttgggcgcca tctccttgca tgcaccattc cttgcggcgg 10320 cggtgctcaa cggcctcaac ctactactgg gctgcttcct aatgcaggag tcgcataagg 10380 gagagcg 10387 <210> 4 <211> 684 <212> DNA <213> Artificial sequence <400> 4 gacaaaactc acacatgccc accgtgccca gcacctgaac tcctgggggg accgtcagtc 60 ttcctcttcc ccccaaaacc caaggacacc ctcatgatct cccggacccc tgaggtcaca 120 tgcgtggtgg tggacgtgag ccacgaagac cctgaggtca agttcaactg gtacgtggac 180 ggcgtggagg tgcataatgc caacaaag ccgcgggagg agcagtacaa cagcacgtac 240 cgtgtggtca gcgtcctcac cgtcctgcac caggactggc tgaatggcaa ggatcaag 300 tgcaaggtct ccaacaaagc cctcccagcc cccatcgaga aaaccatctc caaagccaaa 360 gggcagcccc gagaccaca ggtgtacacc ctgcccccat cccgggagga gatgaccaag 420 aaccaggtca gcctgacctg cctggtcaaa ggcttctatc ccagcgacat cgccgtggag 480 tgggagagca atgggcagcc ggagacac tacaagacca cgcctcccgt gctggactcc 540 gacggctcct tcttcctcta cagcaagctc accgtggaca agagcaggtg gcagcagggg 600 aacgtcttct catgctccgt gatgcacgag gctctgcaca accactacc gcagaagagc ctctccctgt ctccgggtaa atga <210> 5 <211> 9 <212> DNA <213> Artificial sequence <400> 5 ggcggcgga <210> 6 <211> 4269 <212> DNA <213> Artificial sequence <400> 6 ggatctgcga tcgctccggt gcccgtcagt gggcagagcg cacatcgccc acagtccccg agaagttggg gggaggggtc ggcaattgaa cgggtgccta gagaaggtgg cgcggggtaa actgggaaag tgatgtcgtg tactggctcc gccttttttcc cgagggtggg ggagaaccgt 180 atataagtgc agtagtcgcc gtgaacgttc tttttcgcaa cgggtttgcc gccagaacac 240 agctgaagct tcgaggggct cgcatctctc cttcacgcgc ccgccgccct acctgaggcc 300 gccatccacg ccggttgagt cgcgttctgc cgcctcccgc ctgtggtgcc tcctgaactg 360 cgtccgccgt ctaggtaagt ttaaagctca ggtcgagacc gggcctttgt ccggcgctcc 420 cttggagcct acctagactc agccggctct ccacgctttg cctgaccctg cttgctcaac 480 tctacgtctt tgtttcgttt tctgttctgc gccgttacag atccaagctg tgaccggcgc 540 ctacctgaga tcaccggcga aggagggcca ccatgtacag gatgcaactc ctgtcttgca ttgcactaag tcttgcactt gtcacgaatt cggactacca cgatccaagc ctgcccaccc 660. tgagaaaggg cggcggagac taccacgatc cttctctgcc tacactgaga aaaggaggag 720 gcagatctga caaaactcac acatgcccac cgtgcccagc acctgaactc ctggggggac cgtcagtctt cctcttcccc ccaaaaccca aggacaccct catgatctcc cggacccctg 840 aggtcacatg cgtggtggtg gacgtgagcc acgaagaccc tgaggtcaag ttcaactggt 900 acgtggacgg cgtggaggtg cataatgcca agacaaagcc gcgggaggag cagtacaaca gcacgtaccg tgtggtcagc gtcctcaccg tcctgcacca ggactggctg aatggcaagg 1020 agtacaagtg caaggtctcc aacaaagccc tcccagcccc catcgagaaa accatctcca 1080 aagccaaagg gcagccccga gaaccacagg tgtacaccct gcccccatcc cgggaggaga 1140 tgaccaagaa ccaggtcagc ctgacctgcc tggtcaaagg cttctatccc agcgacatcg 1200 ccgtggagtg ggagagcaat gggcagccgg agaacaacta caagaccacg cctcccgtgc 1260 tggactccga cggctccttc ttcctctaca gcaagctcac cgtggacaag agcaggtggc 1320 agcaggggaa cgtcttctca tgctccgtga tgcacgaggc tctgcacaac cactacacgc 1380 agaagagcct ctccctgtct ccgggtaaat gagtgctagc tggccagaca tgataagata 1440 cattgatgag tttggacaaa ccacaactag aatgcagtga aaaaaatgct ttatttgtga 1500 aatttgtgat gctattgctt tatttgtaac cattataagc tgcaataaac aagttaacaa 1560 caacaattgc attcatttta tgtttcaggt tcagggggag gtgtgggagg ttttttaaag 1620 caagtaaaac ctctacaaat gtggtatgga attaattcta aaatacagca tagcaaaact 1680 ttaacctcca aatcaagcct ctacttgaat ccttttctga gggatgaata aggcataggc 1740 atcaggggct gttgccaatg tgcattagct gtttgcagcc tcaccttctt tcatggagtt 1800 taagatatag tgtattttcc caaggtttga actagctctt catttcttta tgttttaaat 1860 gcactgacct cccacattcc ctttttagta aaatattcag aaataattta aatacatcat 1920 tgcaatgaaa ataaatgttt tttattaggc agaatccaga tgctcaaggc ccttcataat 1980 atcccccagt ttagtagttg gacttaggga acaaaggaac ctttaataga aattggacag 2040 caagaaagcg agcttctagc ttatcctcag tcctgctcct ctgccacaaa gtgcacgcag 2100 ttgccggccg ggtcgcgcag ggcgaactcc cgcccccacg gctgctcgcc gatctcggtc 2160 atggccggcc cggaggcgtc ccggaagttc gtggacacga cctccgacca ctcggcgtac 2220 agctcgtcca ggccgcgcac ccacacccag gccagggtgt tgtccggcac cacctggtcc 2280 tggaccgcgc tgatgaacag ggtcacgtcg tcccggacca caccggcgaa gtcgtcctcc 2340 acgaagtccc gggagaaccc gagccggtcg gtccagaact cgaccgctcc ggcgacgtcg 2400 cgcgcggtga gcaccggaac ggcactggtc aacttggcca tgatggctcc tcctgtcagg 2460 agaggaaga gagaaggtt agtacaattg ctatagtgag tgttatta ctagcagat 2520 atactatgcc aatgattaat tgtcaacta gggctgcagg gttcatagtg ccactttcc 2580 tgcactgccc catctcctgc ccaccttc ccaggcatag acagtcagtg acttaccaaa 2640 ctcacaggag ggagaaggca gaagcttgag acagacccgc gggaccgccg aactgcgagg 2700 ggacgtggct agggcggctt cttttggt gcgccggccc tcggaggcag ggcgctcggg 2760 gaggcctagc ggccaatctg cggtggcagg aggcggggcc gaagccgtg cctgaccaat 2820 ccggagcaca taggagtctc agccccccgc cccaagcaa ggggaagtca cgcgcctgta 2880 gcgccagcgt gttgtgaat gggggcttgg gggggttggg gccctgacta gtcaaaacaa 2940 actcccattg acgtcaatgg ggtggagact tggaatccc cgtgagtcaa accgctatcc 3000 acgcccattg atgtactgcc aaaaccgcat catcatggta atagcgatga ctaatacgta 3060 gatgtactgc caagtaggaa agtcccataa ggtcatgtac tggcataat gccaggcggg 3120 ccatttaccg tcattgacgt caatagggg cgtacttggc atatgataca cttgatgtac 3180 tgccaagtgg gcagtttacc gtaaatactc cacccattga cgtcaatgga aagtccctat 3240 tggcgttact atgggaacat acgtcattat tgacgtcaat gggcggggt cgttgggcgg 3300 tcagccaggc gggccattta ccgtaagtta tgtaacgcct gcaggttaat taagaacatg 3360 tgagcaaaag gccagcaaaa ggccaggaac cgtaaaaagg ccgcgttgct ggcgtttttc 3420 cataggctcc gcccccctga cgagcatcac aaaaatcgac gctcaagtca gaggtggcga 3480 aacccgacag gactataaag ataccaggcg tttccccctg gaagctccct cgtgcgctct 3540 cctgttccga ccctgccgct taccggatac ctgtccgcct ttctcccttc gggaagcgtg 3600 gcgctttctc atagctcacg ctgtaggtat ctcagttcgg tgtaggtcgt tcgctccaag 3660 ctgggctgtg tgcacgaacc ccccgttcag cccgaccgct gcgccttatc cggtaactat 3720 cgtcttgagt ccaacccggt aagacacgac ttatcgccac tggcagcagc cactggtaac 3780 aggattagca gagcgaggta tgtaggcggt gctacagagt tcttgaagtg gtggcctaac 3840 tacggctaca ctaagaac agtatttggt atctgcgctc tgctgaagcc agttaccttc 3900 ggaaaaagag ttggtagctc ttgatccggc aaacaaacca ccgctggtag cggtggtttt 3960 tttgtttgca agcagcagat tacgcgcaga aaaaaaggat ctcaagaaga tcctttgatc 4020 ttttctacgg ggtctgacgc tcagtggaac gaaaactcac gttaagggat tttggtcatg 4080 gctagttaat taacatttaa atcagcggcc gcaataaaat atctttattt tcattacatc 4140 tgtgtgttgg ttttttgtgt gaatcgtaac taacatacgc tctccatcaa aacaaaacga 4200 aacaaaacaa actagcaaaa taggctgtcc ccagtgcaag tgcaggtgcc agaacatttc 4260 tctatcgaa 4269
Claims
1. Recombinant human 2DK-Fc fusion protein, characterized in that: The invention is a fusion protein comprising a tumor targeting peptide DK polypeptide repeating sequence and a human immunoglobulin IgG1-Fc fragment, and its amino acid sequence is shown in SEQ ID No.
1.
2. A nucleic acid encoding the recombinant human 2DK-Fc fusion protein according to claim 1, characterized in that: The nucleic acid comprises the sequence shown in SEQ ID No.
2.
3. An expression plasmid pCGS3-GS-2DK-Fc comprising the nucleic acid sequence shown in SEQ ID No.2, characterized in that The nucleic acid sequence of claim 2 is inserted into the expression vector pCGS3-CHOZN-GS. The gene sequence of the expression plasmid pCGS3-GS-2DK-Fc is shown in SEQ ID No.
3.
4. A method for producing the recombinant human 2DK-Fc fusion protein according to claim 1, characterized in that: The protein expression plasmid is designed and constructed by genetic engineering, and is transfected into CHOZN cells for expression, and then separated and purified by affinity chromatography. 5 . A composition comprising the recombinant human fusion protein according to claim 1 , the nucleic acid according to claim 2 , and the expression plasmid pCGS3-GS-2DK-Fc according to claim 3 .
6. Use of the recombinant human 2DK-Fc fusion protein according to claim 1 in the preparation of drugs for treating lung cancer, liver cancer, colon cancer, pancreatic cancer and breast cancer.
